109 results
Page 3 of 6
8-K
EX-99.1
mtj3jouhb7v6o47i7uu
10 May 22
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights
7:37am
8-K
EX-1.1
nhu8 wzof184
19 Apr 22
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
7:30am
424B5
92f1 ek6lsfc
14 Apr 22
Prospectus supplement for primary offering
5:22pm
8-K
EX-99.1
cbqfbrso29m
12 Apr 22
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
7:37am
8-K
mij7cx
12 Apr 22
Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency
7:37am
8-K
EX-99.1
h97hvsr6
4 Apr 22
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
7:39am
8-K
hzgp ynanc63glec
4 Apr 22
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
7:39am
8-K
EX-99.1
50b47b8ec1wfqemh2g
15 Mar 22
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights
5:30pm
8-K
EX-99.1
3brbpxd
8 Mar 22
Inozyme Pharma Strengthens Management Team with Two Executive Appointments
7:41am
S-3
EX-4.3
mtmsfczniu8wlb
11 Aug 21
Shelf registration
7:12am
S-3
fjcl28ogo064 q0pmzp3
11 Aug 21
Shelf registration
7:12am
S-3
EX-4.4
xdinbfw
11 Aug 21
Shelf registration
7:12am
S-3
EX-1.2
qnum3eu ay17g0hl3i
11 Aug 21
Shelf registration
7:12am